Best response to a single dose of 90Y-ibritumomab following first-line treatment with or chemotherapy with rituximab (group B)
| Response . | In patients pretreated with chemotherapy plus rituximab, no. (%) . | ||
|---|---|---|---|
| Group B overall, n = 26 . | Induction failure, n = 13* . | Relapsed from CR, n = 13 . | |
| CR | 1 (4) | — | 1 (7.7) |
| CRu | 2 (8) | 1 (7.7) | 1 (7.7) |
| PR | 2 (8) | 1 (7.7) | 1 (7.7) |
| ORR | 5 (19) | 2 (15) | 3 (23) |
| Response . | In patients pretreated with chemotherapy plus rituximab, no. (%) . | ||
|---|---|---|---|
| Group B overall, n = 26 . | Induction failure, n = 13* . | Relapsed from CR, n = 13 . | |
| CR | 1 (4) | — | 1 (7.7) |
| CRu | 2 (8) | 1 (7.7) | 1 (7.7) |
| PR | 2 (8) | 1 (7.7) | 1 (7.7) |
| ORR | 5 (19) | 2 (15) | 3 (23) |
Includes 4 PRs after first-line chemotherapy + rituximab treatment.